Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM5 Sub-study 7: Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone in RRMM
NCT07150104Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Aug 2022
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 8
01
Overview
A Phase 2 trial of belantamab mafodotin in multiple myeloma (MM), sponsored by GSK. Started Aug 2022; status: active, not recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07150104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07150104.